阿里、腾讯、美团等被总结为建议调出的"老登恒生"成分股。同时，恒生生物科技指数也在当日逆市收 涨0.96%，另外，石油股也出现走强。 值得留意的是，虽然港股互联网主题ETF、恒生科技ETF等节前资金流入最多的ETF并未迎来涨势，但 表现强势的个股也有公募基金的布局身影，次新股以打新的方式布局，而表现强势板块则在此前已有主 动权益基金的加仓迹象。 2月22日，节后首个交易日，恒指和恒生科技虽然没有收涨，但AI概念股的涨势如期而至。 2月20日，港股三大指数集体收跌。其中，恒生科技收跌2.91%，恒生指数收跌1.10%，而恒生国企指数 收跌1.22%。相较于恒生科技的继续下挫，港股上市的AI概念次新股却迎来上涨，网友也出现了调整恒 生科技部分成分股的建议。 小米、中芯国际、比亚迪、腾讯、快手等成分股也在去年四季度被主动权益基金减持，不过，美团在去 年四季度得到主动权益基金增持超过1700万股。 石油、创新药板块走强 港股AI概念股大涨 截至2月20日收盘，智谱延续强势表现，收涨42.72%，报725港元；MiniMax也同样收涨14.52%，报970 港元。两大AI龙头盘中最高市值双双突破3000亿港元，与上市初 ...

Core Insights - The latest holdings of top investment firms reveal a consensus on Pinduoduo and Google as major investments, with significant increases in their positions by several firms [1][2]. Group 1: Segment Analysis - **H&H Investment (Duang Yongping)**: - Total holdings exceed $17.49 billion (approximately 120.8 billion RMB) with 14 stocks. Major increases in positions for Berkshire, Nvidia, Pinduoduo, Google C, and Microsoft, while reducing Apple, Occidental Petroleum, Alibaba, Disney, and ASML [3][4]. - New investments in AI-related stocks include CoreWeave, Credo Technology, and Tempus AI, with respective holdings of 0.12%, 0.12%, and 0.04% [3]. - **Jinglin Asset**: - Total holdings valued at $4.045 billion, with Google becoming the largest position, replacing Meta. Significant reduction in Nvidia holdings by over 60% [5][6]. - **Himalaya Capital (Li Lu)**: - Total holdings of $3.57 billion, with a highly concentrated portfolio where the top five stocks account for 95.96%. Google is the largest holding at 43.86% [7][8]. - **Hillhouse Capital (HHLR)**: - Total holdings around $3.104 billion, focusing heavily on Chinese stocks, with Pinduoduo making up 39.17% of the portfolio [9][10]. - **Oriental Harbor (Dan Bin)**: - Total holdings of $1.316 billion, with significant increases in Google A and Nvidia, while reducing positions in several other stocks [11][12]. - **Gaoyi Asset**: - Total holdings of $683 million, with a concentrated portfolio where Huazhu and Pinduoduo account for 68.25% [13][14].

Group 1 - The US stock market rebounded this week, with all three major indices recording weekly gains, including the S&P 500 and Nasdaq Composite, both up over 1% [2] - Nvidia's upcoming earnings report is seen as a critical indicator for the sustainability of the AI boom, with Oppenheimer expecting results to exceed market expectations, although there are concerns about the difficulty of delivering surprises [4][5] - The software sector's earnings are becoming increasingly important due to the intensifying impact of AI, with BakerAvenue Wealth Management highlighting the need for companies to adapt and innovate [5] Group 2 - The market is facing uncertainty due to President Trump's announcement of a potential increase in tariffs from 10% to 15% on global goods, which may require market participants to digest this new information [3] - Upcoming economic events include speeches from Federal Reserve officials and key economic indicators such as the US consumer confidence index and PPI, which could influence market sentiment [6]

Group 1 - The US stock market rebounded this week, with all three major indices recording gains, including the S&P 500 and Nasdaq Composite, both up over 1% [1] - The Supreme Court's ruling against the Trump administration's large-scale tariffs under the International Emergency Economic Powers Act boosted market sentiment [1] - Trump announced plans to increase the global import tax rate from 10% to 15%, introducing new uncertainty for the market [1] Group 2 - Nvidia's upcoming earnings report is seen as a critical indicator for the sustainability of the AI boom, with expectations for results exceeding market forecasts [2] - The importance of earnings reports from the software sector has increased due to the intensifying impact of AI, with companies needing to adapt and innovate [3] - Despite weakness in tech stocks, sectors like energy, industrials, and consumer staples continue to support index performance [3] Group 3 - Key economic events next week include speeches from Federal Reserve officials and the release of various economic indicators, such as factory orders and consumer confidence [4] - Trump's State of the Union address is scheduled, which may provide insights into his administration's economic policies [4]

Group 1 - Major blue-chip stocks mostly rose, with HSBC Holdings closing at HKD 137.775, up 2.59% from the previous close in Hong Kong [2] - Tencent Holdings closed at HKD 531.758, an increase of 1.87% from the previous close in Hong Kong [2] Group 2 - Tencent Holdings reported a latest price of HKD 522.000, down HKD 11.000 or 2.06%, with an ADR price of HKD 531.758, showing an increase of HKD 9.758 compared to the Hong Kong stock price [3] - Alibaba Group (W) had a latest price of HKD 147.100, down HKD 7.600 or 4.91%, with an ADR price of HKD 150.874, reflecting an increase of HKD 3.774 compared to the Hong Kong stock price [3] - HSBC Holdings had a latest price of HKD 134.300, up HKD 0.100 or 0.07%, with an ADR price of HKD 137.775, indicating an increase of HKD 3.475 compared to the Hong Kong stock price [3]

Group 1 - The pharmaceutical stocks have shown a general upward trend, with notable increases in companies such as Genscript Biotech (up 6.33%), Kintor Pharmaceutical (up 5.23%), and Junshi Biosciences (up 4.39%) [1] - The Chinese innovative drug licensing market has continued its strong growth into 2026, with total transaction amounts exceeding $33.28 billion in the first quarter, surpassing the highest quarterly upfront payment levels of 2025 [1] - According to Open Source Securities, the innovative drug sector has experienced a correction over the past two quarters, but long-term prospects for quality stocks are favorable, suggesting an increase in sector allocation focusing on companies with established overseas opportunities and high clinical data performance [1] Group 2 - Donghai Securities previously indicated that the innovative drug sector is entering a phase of accelerated profit realization by 2025, with companies like Innovent Biologics and Rongchang Biopharmaceutical achieving profitability, while others like 3SBio and Shanghai Yizhong are expected to see significant performance increases [2] - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product volume growth supported by medical insurance becoming the foundation for performance growth, while external collaborations such as BD are crucial for enhancing earnings [2]

Core Insights - HHLR Advisors, a fund management platform under Hillhouse Capital, reported a significant reduction in its U.S. stock holdings, with a total market value of $3.104 billion as of the end of Q4 2025, reflecting a 24% decrease quarter-over-quarter [2][3]. Holdings Overview - HHLR Advisors held a total of 33 stocks at the end of Q4, with Chinese concept stocks remaining a core focus, comprising seven out of the top ten holdings and accounting for 92% of the total market value [3][4]. - The top ten holdings include Pinduoduo, Alibaba, BeiGene, Futu Holdings, Legend Biotech, Arrivent Biopharma, KE Holdings, Webull, Cytek Biosciences, and Clearwater Analytics [3][4]. Major Increases - Pinduoduo (PDD) was the largest holding, with shares increased from 8.59 million to 10.72 million, raising its market value from $1.136 billion to $1.216 billion, which now represents 39% of the portfolio [5]. - Alibaba (BABA) also saw a significant increase in holdings, with shares rising from 3.29 million to 5.43 million, increasing its market value from $588 million to $796 million, now making up 26% of the portfolio [5]. - Together, Pinduoduo and Alibaba account for 65% of HHLR's investment portfolio, establishing them as the "dual core" holdings [5]. New Investments - HHLR Advisors made a new investment in the iShares Bitcoin ETF (IBIT), indicating an exploration into emerging asset classes [7][8]. - Taiwan Semiconductor (TSM) received a slight increase in holdings, with a market value of $3.434 million [8]. Reductions - HHLR Advisors significantly reduced its holdings in Futu Holdings, cutting shares from 3.238 million to 1.63 million, with the market value dropping from $563 million to $268 million [9][10]. - Webull saw a near-complete liquidation, with shares reduced from 33.08 million to 5.97 million [10]. - Other companies such as Baidu, NetEase, and Full Truck Alliance were completely sold off [10].

Core Insights - HHLR Advisors, a fund management platform under Hillhouse Capital, revealed its U.S. stock holdings report as of Q4 2025, showing a total market value of $3.104 billion, a decrease of 24% quarter-over-quarter [2]. Group 1: Portfolio Adjustments - HHLR Advisors held a total of 33 stocks at the end of Q4, with significant adjustments including increased positions in Alibaba, Pinduoduo, and Taiwan Semiconductor, while initiating a position in iShares Bitcoin ETF and reducing holdings in Futu and Webull [3][10]. - The top ten holdings of HHLR Advisors included seven Chinese concept stocks, which accounted for 92% of the total market value, focusing on internet e-commerce leaders, biomedicine, and fintech [5]. Group 2: Major Increases - Pinduoduo (PDD) was the largest holding, with shares increasing from 8.59 million to 10.72 million, raising its market value from $1.136 billion to $1.216 billion, now representing 39% of the portfolio [7]. - Alibaba (BABA) also saw a significant increase in holdings, with shares rising from 3.289 million to 5.43 million, increasing its market value from $588 million to $796 million, now making up 26% of the portfolio [7]. Group 3: New Investments - HHLR Advisors made a new investment in the iShares Bitcoin ETF (IBIT), indicating an exploration into emerging asset classes [11]. - A small increase was noted in Taiwan Semiconductor (TSM), with a market value of $3.434 million at the end of Q4 [11]. Group 4: Reductions and Exits - HHLR Advisors significantly reduced its holdings in Futu Holdings, cutting shares from 3.238 million to 1.63 million, with the market value dropping from $563 million to $268 million [13]. - Webull was nearly fully divested, with holdings decreasing from 3.308 million shares to 597,000 shares [13]. - The firm completely exited positions in Baidu, NetEase, and several other companies [14].

Core Viewpoint - The article discusses the significant decline in the stock prices of ten high-issue-price stocks in the A-share market, with seven of them falling below their issue prices, highlighting the risks associated with high valuations and market sentiment shifts [1][22]. Group 1: Stock Performance - Among the ten stocks, only Stone Technology, Naxin Micro, and BeiGene remain above their issue prices as of mid-February 2026 [6][8]. - The maximum decline from issue prices includes: - CanSino down 69.15% - Wanrun New Energy down 58.54% - Huabao New Energy down 54.93% - Yiqiao Shenzhou down 42.22% - Hemai down 32.82% - Foxit Software down 22.17% - Suocheng Technology down 12.83% [10]. - CanSino experienced a dramatic drop of 93% from its peak price of 797.20 yuan to 63.90 yuan [11][19]. Group 2: Company Backgrounds - Hemai, the highest issue price stock at 557.80 yuan, faced a significant decline after reaching a peak of 1877.43 yuan [12]. - Wanrun New Energy, listed at 299.88 yuan, never reached its issue price after its first day of trading [15]. - Yiqiao Shenzhou, with an issue price of 292.92 yuan, peaked at 353.83 yuan before falling to 73.38 yuan [16]. - CanSino, a COVID-19 vaccine stock, was listed at 209.71 yuan and peaked at 797.20 yuan before its decline [17]. Group 3: Market Conditions and Trends - The high issue prices were driven by market enthusiasm for sectors like hard technology, new energy, and biomedicine during the registration reform period from 2020 to 2023 [5][4]. - The overall market sentiment has shifted, leading to a decline in these stocks as the initial excitement waned [22]. - The article notes that the current new stock market shows a stark contrast, with a recent increase in participation and initial gains, but also warns of accumulating risks [24][26]. Group 4: Investment Implications - The high issue prices and P/E ratios of these stocks are no longer guarantees of company strength, but rather potential warning signs of investment risk [28]. - The article emphasizes that the era of easy profits from new stock subscriptions has ended, requiring more thorough research and disciplined investment strategies [27].

Core Insights - Hillhouse Capital's HHLR Advisors revealed its Q4 2025 holdings, showing a significant portfolio adjustment with a total market value of $3.104 billion, a 24% decrease from the previous quarter [2][3]. Group 1: Portfolio Adjustments - HHLR Advisors increased its positions in Alibaba and Pinduoduo, marking them as core holdings, while also initiating a position in the iShares Bitcoin ETF [2][3][8]. - The top ten holdings include seven Chinese concept stocks, which account for 92% of the portfolio, focusing on internet e-commerce, biomedicine, and fintech sectors [3][6]. Group 2: Major Holdings - Pinduoduo remains the largest holding, with shares increasing from 8.59 million to 10.72 million, raising its market value from $1.136 billion to $1.216 billion, now representing 39% of the portfolio [5][6]. - Alibaba, the second-largest holding, saw its shares rise from 3.289 million to 5.43 million, increasing its market value from $588 million to $796 million, now comprising 26% of the portfolio [5][6]. Group 3: Reductions and Exits - HHLR Advisors significantly reduced its holdings in Futu and Webull, with Futu's shares nearly halved from 3.238 million to 1.63 million, and Webull's shares almost fully liquidated [9][10]. - The firm completely exited positions in Baidu, NetEase, and several other non-core stocks [9][10].